New device could speed up GERD diagnosis and save billions
NCT ID NCT07227506
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new FDA-approved device called MuVI that measures electrical resistance in the esophagus to diagnose GERD and eosinophilic esophagitis. Researchers will enroll 50 adults with chronic esophageal symptoms who are already scheduled for an upper endoscopy. The goal is to see if this device can diagnose these conditions more accurately and cost-effectively than current methods, potentially reducing the need for multiple procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MuVI Esophageal mucosal impedance testing device
What this could lead to
If successful, this device could provide a faster, cheaper, and more accurate way to diagnose GERD and eosinophilic esophagitis, reducing the need for multiple procedures.
What could go wrong
This is a small early study with only 50 participants, so results may not apply to everyone. The device may not be more accurate than current tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••